WILSON JAMES N 4

What Happened James N. Wilson, a director of Corcept Therapeutics (CORT), exercised 100,000 stock options on February 24, 2026. The options had an exercise price of $3.88 per share (100,000 × $3.88 = $388,000). As a net (cashless) settlement, 10,636 shares were withheld to satisfy the exercise price/tax liability (recorded at $36.48 per share, ~ $388,001), and 89,364 shares were transferred without consideration to the James N. Wilson and Pamela D. Wilson Trust (reported as a gift/transfer). The Form 4 was filed on February 26, 2026.

Key Details

• Transaction date: 2026-02-24; Form 4 filed: 2026-02-26 (filed within the typical 2-business-day window).
• Options exercised: 100,000 shares at $3.88 per share (total $388,000).
• Withheld for exercise/taxes: 10,636 shares at $36.48/share (≈ $388,001).
• Transferred as gift to trust: 89,364 shares (no cash consideration).
• Shares owned after transaction: not specified on the Form 4.
• Notable footnotes: F1 = net (cashless) exercise with shares withheld; F2 = transfer to the James N. Wilson and Pamela D. Wilson Trust; F3 = Wilson has voting power over trust-held shares but disclaims beneficial ownership; F4 = options were fully exercisable.

Context

• This was an options exercise with net settlement (shares withheld to cover exercise/taxes), not an open-market purchase or sale. Net/cashless exercises are common and do not necessarily signal a buy or sell intent in the market.
• The 89,364-share transfer was a gift/transfer to a family trust; such transfers are often for estate or family-ownership planning and do not reflect a market-based sale.
• The reporting person disclaims beneficial ownership of the trust shares except for any pecuniary interest, and the filing indicates the options were fully exercisable.